Regulatory

• 13 Jan, 2022
  Spago Nanomedicals phase 1 study with SpagoPix shows clear contrast enhancement and is expanded into new indications
• 13 Jan, 2022
  Spago Nanomedicals fas 1-studie med SpagoPix visar tydlig kontrast och utökas till nya indikationer
• 6 Dec, 2021
  Tumorad® shows good safety in preclinical studies
• 6 Dec, 2021
  Tumorad® visar god säkerhet i prekliniska studier
• 2 Dec, 2021
  Second dose group fully recruited in Spago Nanomedical’s phase 1 study with SpagoPix
• 2 Dec, 2021
  Andra dosgruppen färdigrekyterad i Spago Nanomedicals fas 1-studie med SpagoPix
• 10 Nov, 2021
  Spago Nanomedical delårsrapport januari-september 2021
• 24 Aug, 2021
  Spago Nanomedical halvårsrapport januari-juni 2021
• 3 Aug, 2021
  Spago Nanomedical utser Paul Hargreaves till Chief Development Officer
• 5 May, 2021
  Kommuniké från årsstämma 2021 i Spago Nanomedical AB (publ)